Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb27564 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or F | EXPERIMENTAL | - |
| Single Ascending Dose - Placebo Subcutaneous injection of placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| XmAb27564 | DRUG | Single ascending dose of XmAb27564 |
| Placebo | DRUG | Single dose of placebo |
Inclusion Criteria: * Total body weight 50.0 to 100.0 kg and body mass index (BMI) 19.0 to 35.0 kg/m2 * In good general health with no clinically significant abnormality identified on medical or laboratory evaluation and no history of any clinically significant disorder, condition, or disease. * A ...
XmAb27564 is an investigational small molecule being studied for safety in healthy volunteers. It is in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and pharmacokinetics after a single subcutaneous injection. The drug is not approved and remains in clinical development.
XmAb27564 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker XNCR. The company conducted a Phase 1 clinical trial of the drug in healthy volunteers in the United States.
XmAb27564 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is not FDA approved. It remains investigational and is being studied for safety in healthy volunteers.
XmAb27564 has one completed clinical trial, NCT04857866, titled 'Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers.' This Phase 1, randomized, double-blind, placebo-controlled study enrolled 48 participants in the United States.
XmAb27564 is not FDA approved. It is an investigational drug in Phase 1 clinical development. A single Phase 1 trial in healthy volunteers has been completed, but the drug has not received regulatory approval.